Research and Development Expenses. Research and development expenses increased by 25.4% to RMB4.5 billion (US$0.7 billion) for the fourth quarter of 2020 from RMB3.6 billion for the fourth quarter of 2019.
Research and Development Expenses. Except as otherwise provided in this Agreement, * of all Authorized R&D Expenses (as defined below) incurred by or on behalf of the Parties in connection with their activities other than the Northwest Research Activities and the Medarex Research Activities. Within thirty (30) days after the end of each calendar quarter, each Party shall furnish the Steering Committee with a statement (a) detailing the costs and expenses actually incurred in connection with the research and development activities (including Phase IV and any other post-Regulatory Approval research and development activities) performed by or on behalf of such Party during such calendar quarter, provided that such costs or expenses may not exceed (or be projected to exceed) the amounts set forth in the relevant Project Budget with respect to such research and development activities by more than ten percent (10%) without the approval of the Steering Committee (the "AUTHORIZED R&D EXPENSES") and (b) comparing such expenses to date with the projections set forth in the Project Budget. Within forty-five (45) days after the end of each calendar quarter, Medarex and Northwest shall make payments to one another so that * of the total Authorized R&D Expenses for such calendar quarter. As Filed with the Securities and Exchange Commission on August 10, 2001. *INFORMATION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Research and Development Expenses. Research and development expenses was RMB4.1 billion (US$0.6 billion) for the fourth quarter of 2021, as compared to RMB4.5 billion for the fourth quarter of 2020.
Research and Development Expenses. Notwithstanding anything in Section 6.4 of the U.S. Agreement to the contrary, R&D Expenses that are incurred on or after January 1, 2004 and relate to studies, tests or trials that support regulatory filings related to CAIV-T exclusively in the United States and in no other jurisdictions (“U.S.-Only Expenses”), will be borne (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). Any R&D Expenses that are incurred on or after January 1, 2004 and relate to studies, tests or trials that support regulatory filings related to CAIV-T in the United States and one or more other jurisdictions (“Multi-Jurisdiction Expenses”) will be borne (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). Any R&D Expenses that are incurred after January 1, 2004 and relate to studies, tests or trials to support regulatory filings related to CAIV-T exclusively in jurisdictions outside of the United States (“Ex-U.S. Expenses”) will be borne (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). For the purposes of the three preceding sentences, the term “exclusively” refers solely to the jurisdiction limitation for support of regulatory filings and does not prohibit either Party from fulfilling any disclosure obligations to regulatory authorities in any jurisdiction. For clarity, a complete list of those on-going studies, trials and tests related to CAIV-T for which R&D Expenses are expected to be incurred on or after January 1, 2004 and the amounts that have been budgeted for such studies, trials and tests will be reviewed for approval by the JDC and the JCC no later than December 31, 2003 and will be categorized as U.S.-Only Expenses, Multi-Jurisdiction Expenses or Ex-U.S. Expenses, if and when approved. In accordance with the procedure described in the introductory paragraph of this Section 3, all other studies, trials and tests to be included in the Development Plan and related to CAIV-T will be approved by the JDC or IDC, as applicable and JCC or ICC, as applicable and the related expenses will be designated by the JDC or IDC (subject to final approval by the JCC or ICC) as U.S.-Only Expenses, Multi-Jurisdiction Expenses or Ex-U.S. Expenses, as applicable, at the time of such approval. The Party conducting or sponsoring the study, trial or test will notify the other in writing promptly if the expenses exceed or are expected to exceed the budgeted amount approved by the JCC or ICC by greater than a percentage amount (which percentage amount will be set for the JCC and ICC by the JCC on or before December 3...
Research and Development Expenses. Research and development expenses are expensed as incurred.
Research and Development Expenses. Research and development activities are performed largely by KRATON employees located at Shell’s technology centers in Houston, Texas, The Netherlands, and Belgium.
Research and Development Expenses. From the Effective Date forward, the Parties shall be obligated to and shall fund all Research Expenses and Development Costs on an equal basis, subject to the limitations of Section 5.3.3.
Research and Development Expenses. Except as set forth in Section 2.02, Atrix shall, at its sole expense, be responsible for all research and development expenses pertaining to the Product.
Research and Development Expenses. Except as otherwise provided in this Agreement, [*] and [*] shall [*] ([*]%) [*] the cost and expense of all Authorized R&D Expenses (as defined below) incurred by or on behalf of the Parties in connection with their activities other than the Seattle Genetics Research Activities and the Medarex Research Activities. Within thirty (30) days after the end of each calendar quarter, each Party shall furnish the Steering Committee with a statement (a) detailing the costs and expenses actually incurred in connection with the research and development activities (including Phase IV and any other post-Regulatory Approval research and development activities) performed by or on behalf of such Party during such calendar quarter, provided that such costs or expenses [*] set forth in the relevant Project Budget with respect to such research and development activities by more than [*] ([*]%) without the approval of the Steering Committee (the "Authorized R&D Expenses") and (b) comparing such expenses to date with the projections set forth in the Project Budget. Within forty-five (45) days after the end of each calendar quarter, Medarex and Seattle Genetics shall [*] to [*] so that [*] ([*]%) of the total Authorized R&D Expenses for such calendar quarter.
Research and Development Expenses. (a) Fujisawa shall reimburse Atrix for []** of all Development Costs incurred by Atrix after []** If Fujisawa []** then Atrix shall []**
